JaLCDOI 10.18926/AMO/56873
フルテキストURL 73_3_279.pdf
著者 Makimoto, Go| Nishimori, Hisakazu| Kondo, Reiko| Yanai, Hiroyuki| Sugimoto, Morito| Oda, Naohiro| Kubo, Toshio| Hotta, Katsuyuki| Tabata, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu|
抄録 Urothelial carcinoma usually presents with hematuria, but cases of multiple lymphadenopathy with elevated S-pancreas-1 antigen (SPan-1) levels have not been reported. A 62-year-old Japanese man with lymphadenopathies was diagnosed with an adenocarcinoma of unknown origin and transferred to our hospital for further diagnosis. Serum carbohydrate antigen 19-9 and SPan-1 levels were extremely elevated. Uroplakin III immunostaining was positive in the inguinal lymph node, and cystoscopy revealed the presence of invasive urothelial carcinoma. Treatment with cisplatin and gemcitabine promoted a complete metabolic response for > 4 years. The detection of uroplakin III and serum SPan-1 might help diagnose urothelial carcinoma.
キーワード urothelial carcinoma uroplakin III s-pancreas-1 antigen carbohydrate antigen 19-9 chemotherapy
Amo Type Case Report
発行日 2019-06
出版物タイトル Acta Medica Okayama
73巻
3号
出版者 Okayama University Medical School
開始ページ 279
終了ページ 284
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 31235978
JaLCDOI 10.18926/AMO/56652
フルテキストURL 73_2_161.pdf
著者 Okamoto, Sachiyo| Matsuoka, Ken-ichi| Sakamoto, Maiko| Usui, Yoshiaki| Fujiwara, Yuki| Kondo, Takumi| Tani, Katsuma| Saeki, Kyosuke| Meguri, Yusuke| Asada, Noboru| Ennishi, Daisuke| Nishimori, Hisakazu| Fujii, Keiko| Fujii, Nobuharu| Maeda, Yoshinobu|
抄録 Second allogeneic stem cell transplantation (allo-SCT) is a potentially curative therapy for patients who relapse after first allo-SCT. Human leukocyte antigen (HLA)-haploidentical related donors provide the broad opportunity to conduct second SCT at the appropriate time, but the efficacy of second SCT from haploidentical donors after relapse has not been established. We retrospectively analyzed the records of 33 patients who underwent second SCT. Twenty patients underwent haplo-SCT with low-dose antithymocyte globulin (ATG), and the other 13 patients underwent conventional- SCTs, including HLA-matched related peripheral blood, unrelated bone marrow or cord blood. Three years after the second SCT, the overall survival (OS) and progression-free survival (PFS) of all patients were 32.5% and 23.9%. Multivariate analyses indicated that non-complete response at second SCT, less than 1-year interval to relapse after first- SCT, and total score ≥ 3 on the hematopoietic cell transplantation-specific comorbidity index were significantly associated with a lower PFS rate. The haplo- and conventional- SCT groups showed equivalent results regarding OS, PFS, cumulative incidences of relapse, non-relapse mortality and graft-versus-host disease. The neutropenic period after transplantation was significantly shorter in haplo- SCT than conventional- SCT (10.5 days vs. 16 days, p=0.001). Our analysis revealed that haplo-SCT could be an alternative therapeutic option for relapsed patients after first SCT.
キーワード allogeneic stem cell transplantation haploidentical stem cell transplantation relapse anti-T lymphocyte globulin
Amo Type Original Article
発行日 2019-04
出版物タイトル Acta Medica Okayama
73巻
2号
出版者 Okayama University Medical School
開始ページ 161
終了ページ 171
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2019 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 31015751
JaLCDOI 10.18926/AMO/56249
フルテキストURL 72_5_507.pdf
著者 Ogata, Takeshi| Katsui, Kuniaki| Yoshio, Kotaro| Ihara, Hiroki| Katayama, Norihisa| Soh, Junichi| Kuroda, Masahiro| Kiura, Katsuyuki| Maeda, Yoshinobu| Toyooka, Shinichi| Kanazawa, Susumu|
抄録 To clarify the relationship between dose-volume histogram (DVH) parameters and radiation pneumonitis (RP) after surgery in cases of non-small cell lung cancer (NSCLC) treated with induction concurrent chemoradiotherapy (CCRT). Patients with NSCLC treated with induction CCRT (chemotherapy: cisplatin and docetaxel; radiotherapy: 2.0 Gy fractions once daily for a total of 46 Gy) before surgery were reviewed. We calculated the percentage of lung volume receiving at least 20 Gy (V20) and the mean lung dose (MLD) for the total lung volume and the lung remaining after resection. Factors affecting the incidence of RP at grade 2 or higher (≥ G2 RP) were analyzed. Eighteen of 49 patients (37%) experienced ≥G2 RP. The V20 and MLD for the lung remaining after resection (V20r and MLDr) were significant predictors according to the multivariate analysis (p=0.007 and 0.041, respectively). The incidence of ≥G2 RP was 8% in patients with V20r<10%, and 13% in patients with MLDr<5.6 Gy, respectively. The optimal approach to reduce the rate of postoperative RP in patients with induction CCRT for NSCLC is to keep the V20r below 10% and/or the MLDr below 5.6 Gy in the radiotherapy planning.
キーワード radiation pneumonitis V20 mean lung dose induction chemoradiotherapy non-small cell lung cancer
Amo Type Original Article
発行日 2018-10
出版物タイトル Acta Medica Okayama
72巻
5号
出版者 Okayama University Medical School
開始ページ 507
終了ページ 513
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30369608
JaLCDOI 10.18926/AMO/56080
フルテキストURL 72_3_319.pdf
著者 Makimoto, Go| Ichihara, Eiki| Hotta, Katsuyuki| Ninomiya, Kiichiro| Oze, Isao| Minami, Daisuke| Ninomiya, Takashi| Kubo, Toshio| Ohashi, Kadoaki| Tabata, Masahiro| Maeda, Yoshinobu| Kiura, Katsuyuki|
抄録 Although cisplatin-based chemotherapy shows a survival advantage compared to carboplatin for treating advanced non-small cell lung cancer, high-volume hydration and a long infusion time are necessary to avoid nephrotoxicity, and cisplatin-based chemotherapy has been difficult to administer in outpatient settings. A low-volume hydration method using mannitol or furosemide as forced diuresis was recently introduced, but there are no clear conclusions regarding which agent should be used. We describe our ongoing randomized phase II trial (the OLCSG1406 Study) evaluating the efficacy of forced diuresis. This study will clarify whether mannitol or furosemide is more suitable in cisplatin-based chemotherapy with low-volume hydration.
キーワード cisplatin mannitol furosemide lung cancer hydration non-small cell lung cancer
Amo Type Clinical Study Protocol
発行日 2018-06
出版物タイトル Acta Medica Okayama
72巻
3号
出版者 Okayama University Medical School
開始ページ 319
終了ページ 323
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 29926012
フルテキストURL blood_119_1_285.pdf
著者 Nishimori, Hisakazu| Maeda, Yoshinobu| Teshima, Takanori| Sugiyama, Haruko| Kobayashi, Koichiro| Yamasuji, Yoshiko| Kadohisa, Sachiyo| Uryu, Hidetaka| Takeuchi, Kengo| Tanaka, Takehiro| Yoshino, Tadashi| Iwakura, Yoichiro| Tanimoto, Mitsune|
備考 This research was originally published in Blood. 2012. © the American Society of Hematology.
発行日 2012-01-05
出版物タイトル Blood
119巻
1号
開始ページ 285
終了ページ 295
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン publisher
PubMed ID 22077062
DOI 10.1182/blood-2011-01-332478
Web of Sience KeyUT 000299012400035
関連URL https://doi.org/10.1182/blood-2011-01-332478
フルテキストURL K0005304 other1.pdf
著者 Igawa, Takuro| Sato, Yasuharu| Takata, Katsuyoshi| Iwaki, Noriko| Tanaka, Takehiro| Asano, Naoko| Maeda, Yoshinobu| Orita, Yorihisa| Nakamura, Naoya| Nakamura, Shigeo| Yoshino, Tadashi|
キーワード Cyclin D2 CD5 Diffuse large B-cell lymphoma
備考 学位審査副論文
発行日 2013-05-15
出版物タイトル Diagnostic Pathology
8巻
出版者 BioMed Central
開始ページ 81
ISSN 1746-1596
資料タイプ 学術雑誌論文
言語 English
OAI-PMH Set 岡山大学
著作権者 https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja
論文のバージョン publisher
PubMed ID 23675804
DOI 10.1186/1746-1596-8-81
Web of Sience KeyUT 000319266300002
関連URL https://doi.org/10.1186/1746-1596-8-81 http://ousar.lib.okayama-u.ac.jp/54287